OnCore Login

Return to Trial Database

HCRN-LUN18-335

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Status

Enrollment Closed

Cancer Type(s)

Lung

Study Contact

(317) 921-2050
studies@hoosiercancer.org

Publications

RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC
  • A Saltos, C Baik, RE Sanborn, E Shum, C Kim, R Hall, MJ Fidler, CA Shu, G Otterson, J Patel, KK Wong, N Hanna, J Gray, J Heymach, X Le
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial)
  • X Le, JD Patel, E Shum, C Baik, RE Sanborn, CA Shu, C Kim, MJ Fidler, R Hall, YY Elamin, J Tu, G Blumenschein, J Zhang, D Gibbons, C Gay, NA Mohindra, Y Chae, Y Boumber, J Sabari, R Santana-Davila, S Rogosin, B Herzberg, B Creelan, B Pellini, T Tanvetyanon, S Heeke, M Hernandez, JE Gray, A Saltos, JV Heymach

Trial Locations

All sites in which the trial HCRN-LUN18-335 being conducted in.
MD Anderson Cancer Center
Moffitt Cancer Center
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278